Nerve growth factor for Bell's palsy: A meta-analysis

Su,Yipeng; Dong,Xiaomeng; Liu,Juan; Hu,Yaozhi; Chen,Jinbo

doi:10.3892/etm.2014.2100

Nerve growth factor for Bell's palsy: A meta-analysis

Authors:
- Yipeng Su
- Xiaomeng Dong
- Juan Liu
- Yaozhi Hu
- Jinbo Chen
View Affiliations

Affiliations: Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Library of Binzhou Medical University, Binzhou, Shandong 256603, P.R. China, Department of Neurology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, P.R. China
Published online on: December 3, 2014 https://doi.org/10.3892/etm.2014.2100
Pages: 501-506

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A meta‑analysis was performed to evaluate the efficacy and safety of nerve growth factor (NGF) in the treatment of Bell's palsy. PubMed, the Cochrane Central Register of Controlled Trials, Embase and a number of Chinese databases, including the China National Knowledge Infrastructure, China Biology Medicine disc, VIP Database for Chinese Technical Periodicals and Wan Fang Data, were used to collect randomised controlled trials (RCTs) of NGF for Bell's palsy. The span of the search covered data from the date of database establishment until December 2013. The included trials were screened comprehensively and rigorously. The efficacies of NGF were pooled via meta‑analysis performed using Review Manager 5.2 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the fixed‑effects model. The meta‑analysis of eight RCTs showed favorable effects of NGF on the disease response rate (n=642; OR, 3.87; 95% CI, 2.13‑7.03; P<0.01; I2=0%). However, evidence supporting the effectiveness of NGF for the treatment of Bell's palsy is limited. The number and quality of trials are too low to form solid conclusions. Further meticulous RCTs are required to overcome the limitations identified in the present study.

View Figures

View References

1	Peitersen E: Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 4–30. 2002. View Article : Google Scholar
2	Greco A, Gallo A, Fusconi M, Marinelli C, Macri GF and de Vincentiis M: Bell’s palsy and autoimmunity. Autoimmun Rev. 12:323–328. 2012. View Article : Google Scholar : PubMed/NCBI
3	Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N and Yanagihara N: Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 124:27–30. 1996. View Article : Google Scholar : PubMed/NCBI
4	Lorber B: Are all diseases infectious? Ann Intern Med. 125:844–851. 1996. View Article : Google Scholar : PubMed/NCBI
5	Peitersen E: Natural history of Bell’s palsy. Acta Otolaryngol Suppl. 492:122–124. 1992. View Article : Google Scholar
6	Salinas RA, Alvarez G, Daly F and Ferreira J: Corticosteroids for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. CD0019422010.
7	Lockhart P, Daly F, Pitkethly M, Comerford N and Sullivan F: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. CD0018692009.
8	Baugh RF, Basura GJ, Ishii LE, et al: Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg. 149(3 Suppl): S1–S27. 2013. View Article : Google Scholar : PubMed/NCBI
9	Ebendal T: Function and evolution in the NGF family and its receptors. J Neurosci Res. 32:461–470. 1992. View Article : Google Scholar : PubMed/NCBI
10	Chao MV, Rajagopal R and Lee FS: Neurotrophin signalling in health and disease. Clin Sci (Lond). 110:167–173. 2006. View Article : Google Scholar
11	Deppmann CD, Mihalas S, Sharma N, Lonze BE, Niebur E and Ginty DD: A model for neuronal competition during development. Science. 320:369–373. 2008. View Article : Google Scholar : PubMed/NCBI
12	Apfel SC: Neurotrophic factor therapy - prospects and problems. Clin Chem Lab Med. 39:351–355. 2001. View Article : Google Scholar : PubMed/NCBI
13	Egger M, Smith GD and Altman DG: Systematic Reviews in Health Care: Meta-Analysis in Context. Second edition. John Wiley & Sons, Inc; Hoboken, NJ: 2008
14	Sullivan FM, Swan IR, Donnan PT, et al: Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 357:1598–1607. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yeo SG, Lee YC, Park DC and Cha CI: Acyclovir plus steroid vs steroid alone in the treatment of Bell’s palsy. Am J Otolaryngol. 29:163–166. 2008. View Article : Google Scholar : PubMed/NCBI
16	De Diego JI, Prim MP, De Sarriá MJ, Madero R and Gavilán J: Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. Laryngoscope. 108:573–575. 1998. View Article : Google Scholar : PubMed/NCBI
17	Suai Z, Suqin L and Xuhua C: The clinical efficacy of the treatment of Bell’s palsy by nerve growth factor in 45 patients. Lin Chuang Shen Jing Bing Za Zhi. 19:3922006.(In Chinese).
18	Xiaomei T and Ye W: Outcome of treatment with nerve growth fator in patients with Bell’s palsy. Lin Chuang Yi Xue. 28:23–24. 2008.(In Chinese).
19	Guofen Z: Outcome of treatment with nerve growth factor in 30 patients with Bell’s palsy. Lin Chuang He Li Yong Yao. 3:422010.(In Chinese).
20	Mo J, Huang Y and Zhou W: The efficacy of mouse nerve growth factor for injection in idiopathic facial paralysis. Zhong Guo Yi Yao Zhi Nan. 20:32–33. 2011.(In Chinese).
21	Liu XD: The efficacy of mouse nerve growth factor for idiopathic facial paralysis in 58 patients. Zhong Guo Zhong Xi Yi Jie He Er Bi Yan Hou Ke Za Zhi. 20:462–463. 2012.(In Chinese).
22	Wang Z, Ma MJ and Han Q: Analysis the efficacy of nerve growth factor in the treatment of facial paralysis. Shen Jing Sun Shang Yu Gong Neng Chong Jian. 7:286–288. 2012.(In Chinese).
23	Li GS, Wu SG, Liu XF, Li P and Long ZZ: Clinical efficacy analysis of the nerve growth factor in the treatment of facial neuritis. Hei Long Jiang Yi Xue. 37:927–928. 2013.(In Chinese).
24	Jianwei T and Chuan D: The observation of nerve growth factor for idiopathic facial paralysis. Jian Kang Da Shi Ye :Yi Xue Ban. 21:46–47. 2013.(In Chinese).
25	Schulz KF, Chalmers I, Hayes RJ and Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273:408–412. 1995. View Article : Google Scholar : PubMed/NCBI
26	Ernst E and Lee MS: A trial design that generates only ‘positive’ results. J Postgrad Med. 54:214–216. 2008. View Article : Google Scholar : PubMed/NCBI
27	Levi-Montalcini R: The nerve growth factor 35 years later. Science. 237:1154–1162. 1987. View Article : Google Scholar : PubMed/NCBI
28	Cohen S, Levi-Montalcini R and Hamburger V: A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA. 40:1014–1018. 1954. View Article : Google Scholar
29	Shao H, Shu H, Wang C, Yuan W and Li Y: Expression of nerve growth factor and its receptor in distracted tibial nerve after limb lengthening. Anat Rec (Hoboken). 296:333–339. 2013. View Article : Google Scholar
30	Yildiz M, Karlidag T, Yalcin S, et al: Efficacy of glial growth factor and nerve growth factor on the recovery of traumatic facial paralysis. Eur Arch Otorhinolaryngol. 268:1127–1133. 2011. View Article : Google Scholar : PubMed/NCBI